Back to Results

Chemomab Therapeutics Ltd DRC (CMMB)

Chemomab Therapeutics Ltd. DRC (NASDAQ: CMMB) is a depositary receipt representing common stock of Chemomab Therapeutics Ltd., a clinical-stage biotechnology company focused on developing therapies for fibrotic and inflammatory diseases. The company’s lead candidate is nebokitug, a humanized monoclonal antibody designed to modulate CCL24 and its role in inflammatory and fibrotic pathways. Nebokitug has completed a phase 2 trial in primary sclerosing cholangitis and is also being evaluated in a phase 2 study for systemic sclerosis. Chemomab Therapeutics was founded in 2011 and is based in Tel Aviv-Yafo, Israel.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-CMMB
$2.06
-13.6% Downside
Fair
$5
110.1% Upside
Bargain
Good
0.0%
November 6, 2026
2.1x
17.245 M
11.282 M
0.0%
83.7%
-27.5
115.7%
Valuation • Fair Value

Chemomab Therapeutics Ltd DRC (NASDAQ-CMMB) Fair Value by Valuation Model

Review the available estimates for Chemomab Therapeutics Ltd DRC (NASDAQ-CMMB), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$2.06

Estimated downside of 13.6% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$1.97

Discounted cash flow valuation reference.

Comps Fair Value

$2.11

Comparable-company valuation reference.

Analyst Price Target

$5

Analysts imply upside of 110.1%.

How to read these valuation models

Use the 5 available valuation references for Chemomab Therapeutics Ltd DRC (NASDAQ-CMMB) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Chemomab Therapeutics Ltd DRC (NASDAQ-CMMB)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-7.851 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Chemomab Therapeutics Ltd DRC (NASDAQ-CMMB) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Chemomab Therapeutics Ltd DRC (NASDAQ-CMMB)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Altman Z-Score

-27.5

Lower score that deserves closer risk review.

FCF / Net Income

115.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Chemomab Therapeutics Ltd DRC (NASDAQ-CMMB). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Chemomab Therapeutics Ltd DRC (NASDAQ-CMMB)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 6, 2026

Days to Earnings

45

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Chemomab Therapeutics Ltd DRC (NASDAQ-CMMB), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Chemomab Therapeutics Ltd DRC (NASDAQ-CMMB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Chemomab Therapeutics Ltd DRC (NASDAQ-CMMB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Sell

The daily technical read for Chemomab Therapeutics Ltd DRC (NASDAQ-CMMB) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Chemomab Therapeutics Ltd DRC (NASDAQ-CMMB) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Neutral

The monthly technical read for Chemomab Therapeutics Ltd DRC (NASDAQ-CMMB) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Chemomab Therapeutics Ltd DRC (NASDAQ-CMMB) Stock FAQ

Data-supported answers about Chemomab Therapeutics Ltd DRC (NASDAQ-CMMB), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$2.06
Estimated downside 13.6%
Valuation Rating
Overvalued
Estimated downside of 13.6%
Analyst Target
$5
Implied upside 110.1%
Financial Health
Good
Current financial-health read

The current fair value estimate for Chemomab Therapeutics Ltd DRC (NASDAQ-CMMB) is $2.06. This implies an estimated downside of 13.6% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 13.6% versus the current market price.

The available analyst price target for Chemomab Therapeutics Ltd DRC (NASDAQ-CMMB) is $5. The analyst target implies estimated upside of 110.1%.

The current financial health read for Chemomab Therapeutics Ltd DRC (NASDAQ-CMMB) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Chemomab Therapeutics Ltd DRC (NASDAQ-CMMB) is November 6, 2026.

The latest available data indicates no current dividend yield for Chemomab Therapeutics Ltd DRC (NASDAQ-CMMB).

The current market capitalization listed for Chemomab Therapeutics Ltd DRC is 17.245 M.

The current enterprise value listed for Chemomab Therapeutics Ltd DRC is 11.282 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Chemomab Therapeutics Ltd DRC is NASDAQ-CMMB, and the stock is listed on NASDAQ.

Chemomab Therapeutics Ltd DRC (NASDAQ-CMMB) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Chemomab Therapeutics Ltd DRC is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Chemomab Therapeutics Ltd DRC is 83.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B